Meeting abstract
https://doi.org/10.26800/LV-145-supl2-CR31
Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab
Karla Lauš
; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek
Hrvoje Centner
Ema Schönberger
Silvija Canecki-Varžić
Abstract
Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tounderstand immune-related adverse events that comes with it.
Keywords
diabetes mellitus; diabetic ketoacidosis; pembrolizumab
Hrčak ID:
303546
URI
Publication date:
23.4.2023.
Visits: 197 *